This week, the EMCDDA has launched a call to scientists interested in applying to be on a list of experts who may assist the European Union Drugs Agency (EUDA) in the risk assessment of new psychoactive substances (NPS). The EUDA, which will replace the EMCDDA, will begin operations on 2 July 2024, the day on which its founding regulation enters into application.
For the purpose of assessing the risks of NPS, the Scientific Committee may be extended as considered necessary by the Executive Director, acting on the advice of the Chair of the Scientific Committee. This entails designating experts from the list who represent the scientific fields relevant for a balanced risk assessment of the substance(s) concerned.
Risk assessment meetings are held on an ad hoc basis in Lisbon in accordance with Article 10 of the EUDA Regulation. English will be the working language of the risk assessment procedure and meetings.
The selected experts will be included on a list to be approved by the EUDA Management Board for a four-year period. Experts are appointed in a personal capacity and, acting in the public interest, will offer opinions independently of the Member States and EU institutions. They will neither seek, nor take, instructions from any government or from any other body.
Experts must be nationals of an EU Member State or of a country which has concluded an agreement with the agency to participate in its work. Upon appointment, each expert will sign a declaration of independence in relation to the performance of his/her duties in, and for, this body. They will also sign a written declaration of interest.
Deadline for applications: 17.01.2024.
About the EUDA
On 2 July 2024, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) will become the European Union Drug Agency (EUDA) in accordance with Regulation (EU) 2023/1322 of the European Parliament and of the Council of 27 June 2023 on the European Union Drugs Agency (EUDA) and repealing Regulation (EC) No 1920/2006. For additional information on the EUDA, please see New legislation grants Europe stronger powers to tackle current and future drug problems
